The incidence of Venous Thromboembolism (VTE) in patients with pancreatic cancer is
high, especially in individuals with locally advanced or metastatic disease treated
with chemotherapy, as outlined in this retrospective study where the incidence reaches
22% [
[1]
].- García Adri´an S.
- Gonz´alez A.R.
- de Castro E.M.
- et al.
Incidence, risk factors, and evolution of venous thromboembolic events in patients
diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient
basis.
Eur. J. Intern. Med. 2022; https://doi.org/10.1016/j.ejim.2022.07.020
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Incidence, risk factors, and evolution of venous thromboembolic events in patients diagnosed with pancreatic carcinoma and treated with chemotherapy on an outpatient basis.Eur. J. Intern. Med. 2022; https://doi.org/10.1016/j.ejim.2022.07.020
Debourdeau P., Lamblin A., Debourdeau T. et al. Venous thromboembolism associated with central venous catheters in patients with cancer: From pathophysiology to thromboprophylaxis, areas for future studies. J Thromb Haemost. 2021 Nov;19(11):2659-2673. https://onlinelibrary.wiley.com/doi/10.1111/jth.15487.
- 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.Lancet Oncol. 2022; 23: e334-e347https://doi.org/10.1016/s1470-2045(22)00160-7
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood Adv. 2021; 23 (5): 927-974https://doi.org/10.1182/bloodadvances.2020003442
Article info
Publication history
Published online: November 25, 2022
Accepted:
November 14,
2022
Received in revised form:
November 3,
2022
Received:
October 11,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
